anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Under the Diagnostic and Statistical Manual of Mental Disorders (5th ed.), language impairment can co-occur with autism. It is not yet clear how research defines, reports, and characterizes structural language abilities of autistic individuals eligible for school-based special education services (aged 3-21 years) in the United States. In the United States, students typically must be formally diagnosed to be eligible for services and supports. However, the quality of diagnosis is only as good as the research evidence on which diagnosis depends. To evaluate evidence quality, we examined how studies of school-aged autistic individuals report assessments of language ability. This systematic review included 57 studies using English language age-referenced assessments used to measure structural language. Findings showed many differences across studies in how language abilities were measured and reported. Also, none of the studies fully reported the variables relevant to characterizing language impairment. Outcomes were similar across versions of the Diagnostic and Statistical Manual of Mental Disorders. Findings indicate that researchers and clinicians should pay attention to reporting diagnostic and grouping criteria. Carefully interpreting research evidence is critical for ensuring that diagnostic criteria and supports are representative of and accessible to autistic individuals and relevant parties.
BACKGROUND: Epigenetics contributes to the pathogenesis of amyotrophic lateral sclerosis (ALS). We aimed to characterize the DNA methylation profiles associated with clinical heterogeneity in disease progression and survival among patients.
METHODS: We included a cohort of 41 patients with sporadic ALS, with a median follow-up of 86.9 months, and 27 rigorously matched healthy controls. Blood-based genome-wide DNA methylation analysis was conducted.
RESULTS: A total of 948 progression rate-associated differentially methylated positions, 298 progression rate-associated differentially methylated regions (R-DMRs), 590 survival time-associated DMPs, and 197 survival time-associated DMRs (S-DMRs) were identified, using complementary grouping strategies. Enrichment analysis of differentially methylated genes highlighted the involvement of synapses and axons in ALS progression and survival. Clinical analysis revealed a positive correlation between the average methylation levels of the R-DMR in PRDM8 and disease progression rate (r = 0.479, p = 0.002). Conversely, there was an inverse correlation between the average methylation levels of the R-DMR in ANKRD33 and disease progression rate (r = - 0.476, p = 0.002). In addition, patients with higher methylation levels within the S-DMR of ZNF696 experienced longer survival (p = 0.016), while those with elevated methylation levels in the S-DMR of RAI1 had shorter survival (p = 0.006).
CONCLUSION: DNA methylation holds promise as a potential biomarker for tracking disease progression and predicting survival outcome and also offers targets for precision medicine.
The invention relates to a Chinese herbal medicine preparation for treating male infertility as well as the preparation method, belonging to the technical field of medicine, with a view to solve the problem of adopting pure Chinese herbal medicine to treat male infertility. The technical proposal is that the medicine preparation comprises the active pharmaceutical ingredients of the following weight accounts: cassia bark 30 to 130, semen allii tuberose 50 to 300, herba epimedii 15 to 110, medicinal indianmulberry root 20 to 100 and black aconite 20 to 120. The above active pharmaceutical ingredients are made into pills via mixing, crushing into powder and stirring. The medicine preparation treats male infertility according to the concept of wholism and the principle of differentiation of signs. The square of the medicine preparation is attempted and practiced again and again to decide the relationship between the dose of the medicine and the compatibility. The medicine preparation has the functions of enriching the Qi, nourishing the blood, warming the sperm ventricle, benefiting the kidney, enriching the essence and treating the impotence, and satisfying curative effect with 76% as the cure rate, 22% as the effective rate and 98% as the overall response rate for clinically treating male infertility caused by cacospermia, no liquification of semen, impotence and involuntary ejaculation. The medicine preparation is refined into pills via mixture making, washing and choosing and crushing into powder. The medicine preparation has the advantage of convenient use and light patients will cure after taking the medicine for a course of the treatment.
Premarin Intravenous (conjugated estrogens, USP) for injection contains a mixture of conjugated estrogens obtained exclusively from natural sources, occurring as the sodium salts of water-soluble estrogen sulfates blended to represent the average composition of materials derived from pregnant mares' urine. It is a mixture of sodium estrone sulfate and sodium equilin sulfate. It contains as concomitant components, as sodium sulfate conjugates, 17α-dihydroequilin, 17α-estradiol, and 17β-dihydroequilin.

Each single-dose vial contains 25 mg/vial of conjugated estrogens, USP, in a sterile lyophilized cake which also contains lactose 200 mg, sodium citrate 12.2 mg, and simethicone 0.2 mg. The pH is adjusted with sodium hydroxide or hydrochloric acid. The reconstituted solution is suitable for intravenous or intramuscular injection.
Alisertib 25 mg, tablet, orally, twice daily, (3 days on/4 days off for 3 weeks) on Days 1 to 3, 8 to 10 and 15 to 17 in 28 day cycles in combination with Paclitaxel 60 mg/m\^2, intravenous (IV), on Days 1, 8, and 15 in 28-day cycle until disease progression or unacceptable toxicity. Dose of alisertib will be de-escalated to 20 mg if ≥ 2 participants experience a dose limiting toxicity (DLT).
The present invention relates to a composition which is capable of diagnosing, preventing or treating ovarian cancer on the basis of an nc886 gene expression level. The present invention also relates to an information providing method for predicting the prognosis of ovarian cancer patients by confirming an ovarian cancer subtype and an nc886 gene expression level in ovarian cancer patients. Herein, the information providing method includes an information providing method for identifying the nc886 gene expression level with expression patterns of other genes related to nc886. The present invention also relates to a use of a composition for predicting an ovarian cancer prognosis, the composition comprising an agent for measuring the nc886 gene expression level. Therefore, the present invention can exhibit an effect of preventing or treating ovarian cancer by inhibiting nc886 gene expression and can diagnose ovarian cancer or predict the prognosis of ovarian cancer patients by measuring the nc886 gene expression level. In addition, the present invention analyzes the nc886 expression level to predict ovarian cancer metastasis or resistance to an anticancer agent and thus is effective as an information providing method for predicting an ovarian cancer prognosis.
Because of the potential for life threatening events, caution should be taken to ensure that precipitates have not formed in any parenteral nutrition mixture. 

Perform all manipulations in a suitable work area, such as a laminar flow hood. 

Failure to follow the Mixing Guidelines and Limitations below, including recommended storage temperature, storage time, order of mixing, etc., may result in an unstable admixture.

Intralipid 20% (A 20% I.V. Fat Emulsion) may be mixed with Amino Acid and Dextrose Injections where compatibility have been demonstrated. Additives known to be incompatible should not be used. Please consult with pharmacist. If, in the informed judgment of the physician, it is deemed advisable to introduce additives, use aseptic technique. Mix thoroughly when additives have been introduced. Do not store solutions containing additives (e.g., Vitamins and Minerals). Protect the admixed PN solution from light. 

Protect the admixed PN solution from light. 

When being mixed the following proper mixing sequence must be followed to minimize pH related problems by ensuring that typically acidic Dextrose Injections are not mixed with lipid emulsions alone: 

  1. Transfer Dextrose Injection to the TPN (Total Parenteral Nutrition) Admixture Container 
  2. Transfer Amino Acid Injection 
  3. Transfer Intralipid 20% 



Note: Amino Acid Injection, Dextrose Injection and Intralipid 20% may be simultaneously transferred to the admixture container using an automatic mixer. Admixing should be accompanied by gentle agitation to avoid localized concentration effects. 

Additives must not be added directly to Intralipid 20% (A 20% I.V. Fat Emulsion) Pharmacy Bulk Package and in no case should Intralipid 20% be added to the TPN container first. Bags should be shaken gently after each addition to minimize localized concentration. 

If the admixture is not used immediately, the in-use storage time and conditions prior to use are the responsibility of the user and should normally not be longer than 24 hours at 2-8°C. After removal from storage at 2-8°C, the admixture should be infused within 24 hours. 

It is essential that the admixture be prepared using strict aseptic techniques as this nutrient mixture is a good growth medium for microorganisms. 

Supplemental electrolytes, trace metals or multivitamins may be required in accordance with the prescription of the attending physician. 

The prime destabilizers of emulsions are excessive acidity (low pH) and inappropriate electrolyte content. Careful consideration should be given to addition of divalent cations (Ca++ and Mg++) which have been shown to cause emulsion instability. Amino acid solutions exert a buffering effect protecting the emulsion. The admixture should be inspected carefully for “breaking or oiling out” of the emulsion. “Breaking or oiling out” is described as the separation of the emulsion and can be visibly identified by a yellowish streaking or the accumulation of yellowish droplets in the admixed emulsion. The admixture should also be examined for particulates. The admixture must be discarded if any of the above is observed.
Mutations to the tumor suppressor protein p53 have been observed in 40-60% of all human cancers. These mutations are often associated with high nuclear and cytoplasmic concentrations of p53. Since many tumors exhibit highly elevated p53 levels, the protein is an attractive target for cancer immunotherapy.  Unfortunately, p53 is an autoantigen that is likely to be tolerated as a self-protein by the immune system. The present invention is based on the discovery that this self-tolerance can be overcome by administration of recombinant modified vaccinia Ankara (MVA) containing a nucleic acid that encodes p53 (rMVAp53). The invention discloses a method of generating a p53-specific CTL  response to tumor cells expressing mutated p53 by administering a composition comprising rMVAp53. Administration of rMVAp53 decreases tumor development, tumor growth, and mortality in a variety of malignant cell types. These effects are enhanced by administration of CTLA-4 blocker and/or CpG  oligodeoxynucleotide immunomodulators.
LIBERVANT is indicated for treatment in patients 2 to 5 years of age [see Indications and Usage (1)].  LIBERVANT is not approved for use in adults.

Clinical studies of LIBERVANT did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.

A study of single dose IV administration of diazepam (0.1 mg/kg) indicates that the elimination half-life of diazepam increases linearly with age, ranging from about 15 hours at 18 years (healthy young adults) to about 100 hours at 95 years (healthy elderly) with a corresponding decrease in clearance of free diazepam.

If used in elderly patients, LIBERVANT should be used with caution because of an increase in half life with a corresponding decrease in the clearance of free diazepam [see Clinical Pharmacology (12.3)]. It is also recommended that the dosage be decreased to reduce the likelihood of ataxia or oversedation.
In the design of extracorporeal carbon dioxide removal (ECCO2R) combined with continuous renal replacement therapy (CRRT) equipment, the pre dilution replacement solution for continuous veno-venous hemofiltration (CVVH) enters the extracorporeal bloodstream upstream of the membrane lung, so the HCO3- concentration in the pre membrane lung blood is diluted by the replacement solution. HCO3- and dissolved CO2 are in a dynamic and rapid equilibrium state, and a decrease in HCO3- leads to a decrease in PCO2. On the other hand, in continuous veno-venous hemodialysis (CVVHD), the blood after the membrane needs to undergo material exchange with the dialysate through a filter. The dialysate is usually HCO3- with normal plasma concentration, so HCO3- in post membrane blood will exchange interaction. The exchange results of HCO3- determine the impact of CVVHD on the CO2 removal efficiency of the ECCO2R combined CRRT system. This study aims to investigate the effects of CVVH and CVVHD on in vitro CO2 clearance efficiency.
Subjects in this group will receive 3 grams of N-acetylcysteine in 500 cc normal saline (0.9% Sodium Chloride) over 30 minutes prior to contrast administration. After contrast administration, they will receive a continuous infusion of 200 mg N-acetylcysteine per hour. This dose will be administered as an infusion of 67 cc per hour of a solution of 3 grams of N-acetylcysteine in 1000 cc of normal saline. The infusion will be administered for a minimum of two hours and then stopped after 24 hours, or when the patient is discharged from the Emergency Department or the hospital, whichever comes first.
Glycemia-lowering effects of American ginseng root have been repeatedly observed in healthy individuals and in type 2 diabetes. It is unclear which components trigger these effects. Pre-clinical evidence suggests that, aside from ginseng saponins, ginseng polysaccharides may reduce glycemia. This assumption has not been investigated so far in humans.

We therefore undertook a double-blind randomized controlled clinical trial to determine the effect of American ginseng root polysaccharides, at escalating doses, on postprandial glycemia, in comparison to the American ginseng root and control in healthy individuals. We hypothesized that polysaccharides will reduce glycemia comparably to a dose of ginseng root that contains polysaccharides at an equivalent amount to the average polysaccharide dose. We therefore tested polysaccharide doses equivalent to 9, 12 and 15 g of rot, 12 go of ginseng root and a wheat bran control. Each subject received each treatment in random sequence, after a 12-hour overnight fast and 40 minutes prior to a 25-g oral glucose tolerance test. Capillary blood samples were collected at baseline, prior to glucose ingestion and at 15, 30, 45, 60, 90, 120 minutes after the start of glucose intake. Capillary blood glucose was measured.
BACKGROUND: Mesenchymal stromal cells are suggested to play a critical role in Crohn's disease [CD]-associated fibrosis. MAPKAPK2 [MK2] has emerged as a potential therapeutic target to reduce inflammation in CD. However, the cell-specific pattern of phospho-MK2 activation and its role in CD-associated fibrosis are unknown. The objectives of this study were to evaluate cell-specific changes in MK2 activity between predominantly inflammatory CD vs CD with fibrotic complications and define the role of stromal cell-specific MK2 activation in CD-associated fibrosis.
METHODS: CD tissue, CD tissue-derived mesenchymal stromal cells known as myo-/fibroblasts [CD-MFs], and fibroblast-specific MK2 conditional knockout [KO] mice were used.
RESULTS: In the inflamed area of predominantly inflammatory CD, high MK2 activity was equally distributed between mesenchymal and haematopoietic cells. By contrast, in CD with fibrotic complications, high MK2 activity was mostly associated with mesenchymal stromal cells. Using ex vivo CD tissue explants and an IL-10KO murine colitis model, we demonstrated that pro-fibrotic responses are significantly reduced by treatment with the MK2 inhibitor PF-3644022. Inhibition of MK2 activity in primary cultures of CD-MFs significantly reduced basal and TGF-β1-induced profibrotic responses. Using fibroblast-specific MK2 knockout mice in chronic dextran saline sulphate colitis, we demonstrated that fibroblast intrinsic MK2 signalling is among the key processes involved in the chronic inflammation-induced profibrotic responses.
CONCLUSIONS: Our data suggest that activation of MK2 within fibroblasts contributes to the chronic inflammation-induced fibrosis in CD and that targeting MK2 has potential for the development of novel therapeutic approaches for fibrosis in CD.
Cohort 2, Arm A, 400 Inarigivir daily in addition to their prestudy nucleoside/nucleotide (NUC) analogue inhibitors for 48 weeks. At Week 48 subjects will stop both inarigivir and the NUC and be followed for a further 48 weeks off treatment.
Fibrosis regardless of aetiology is characterised by persistently activated myofibroblasts that are contractile and secrete excessive amounts of extracellular matrix molecules that leads to loss of organ function. Damage-Associated Molecular Patterns (DAMPs) are endogenous host-derived molecules that are released from cells dying or under stress that can be triggered by a variety of insults, either chemical or physical, leading to an inflammatory response. Among these DAMPs is S100A4, part of the S100 family of calcium binding proteins that participate in a variety of cellular processes. S100A4 was first described in context of cancer as a pro-metastatic factor. It is now appreciated that aside from its role in cancer promotion, S100A4 is intimately involved in tissue fibrosis. The extracellular form of S100A4 exerts its effects through multiple receptors including Toll-Like Receptor 4 and RAGE to evoke signalling cascades involving downstream mediators facilitating extracellular matrix deposition and myofibroblast generation and can play a role in persistent activation of myofibroblasts. S100A4 may be best understood as an amplifier of inflammatory and fibrotic processes. S100A4 appears critical in systemic sclerosis pathogenesis and blocking the extracellular form of S100A4 in vivo in various animal models of disease mitigates fibrosis and may even reverse established disease. This review appraises S100A4's position as a DAMP and its role in fibrotic conditions and highlight therapeutically targeting this protein to halt fibrosis, suggesting that it is a tractable target.
This pilot study assessed the feasibility of implementing a pain assessment information visualization (InfoViz) tool to address cultural and language barriers among limited English proficiency (LEP) Hmong patients in primary care. We used a static group comparison design to collect data from 20 patient, interpreter, and provider triads under usual care (i.e., interpreter using verbal pain descriptions), followed by another 20 triads under the intervention (i.e., interpreter using verbal pain descriptions and the InfoViz tool). Feasibility outcomes included recruitment and retention rates, InfoViz tool completion, acceptability, and fidelity. We also assessed mutual understanding (MU) and pain electronic health record (EHR) documentation. Descriptive data were calculated and thematic analysis was conducted. Thirty-six LEP Hmong patients (n = 29 female, mean age = 59.03), 27 providers (n = 15 female), and four interpreters participated in this study. The patient recruitment rate was 18% while the retention rate was 81%. Interpreter recruitment rate was 80%, and 75% for retention rate. The intervention fidelity mean score was 83%. In the intervention condition, patient-provider MU of pain severity improved by 30%, coupled with a 28% increase in pain severity EHR documentation compared to usual care. While communication of pain quality did not improve, there was a higher mean number of pain descriptors (3.31 in the intervention vs. 1.79 in usual care) in EHR documentation. All participants had a positive experience with the tool, reporting it as valuable with 100% completeness of all tools. Findings revealed the tool was acceptable and feasible to use among LEP patients-interpreters-providers, providing support for an efficacy study.
The present invention discloses the new application of oxidized matrine (ammothamnine) to the preparation of medicaments for treating nephrotic syndrome hemorrhagic fever. Oxidized matrine has low toxicity and safe and convenient clinical application. The experimental research on oxidized matrine inside and outside viruses of nephrotic syndrome hemorrhagic fever shows that oxidized matrine has low toxic action to cells and performs the function for directly killing viruses of nephrotic syndrome hemorrhagic fever, and the oxidized matrine can obviously inhibit the proliferation of the viruses. Oxidized matrine performs obvious protective function to hamsters infected the viruses, so the disease time is delayed, the disease route is prolonged, and the mortality is reduced. Clinical experiments and research indicate that oxidized matrine has a certain effect on the control of the virus infection. Oxidized matrine can quicken heat removal time, can improve the renal functions, can reduce bleeding, can improve the liver functions and can reduce the occurrence of oliguria stages; therefore, oxidized matrine is an effective safe medicament for treating nephrotic syndrome hemorrhagic fever.
PROBLEM TO BE SOLVED: To obtain the subject composition which affords sufficient dyeing property and high conditioning effect and possesses viscosity stability by adjusting an aqueous solution containing an aromatic alcohol and a direct dye with an acid in a specific pH range and then adding a water-soluble anionic polymer and a cationic polymer. SOLUTION: This composition is obtained by mixing (A) an aromatic alcohol (e.g. benzyl alcohol and the like) with (B) a cationic compound (e.g. a hydroxyethylcellulose dimethyldiallyl ammonium chloride copolymer and the like), (C) a water-soluble anionic polymer (e.g. a carboxyvinyl polymer and the like), (D) a direct dye (e.g. 4-nitro-o-phenylenediamine and the like) and an organic acid or an inorganic acid (e.g. citric acid, hydrochloric acid, etc.), and adjusting pH to 1.5-4 and viscosity to 1,000 centistokes or more. The components D and E in the above component are preferably formulated in amounts of 0.1-5 wt.% and 0.1-15 wt.%, respectively.